Abbott: Argus Research cuts to hold from buy
ABT•Argus Research cut its rating on Abbott to hold from buy.
Related News
Nuwellis Aquadex study shows 87% survival during treatment in pediatric patients
NUWE•
PhotonDelta says manufacturing scale drives competitiveness in integrated photonics
SMH•
Stryker joins Jefferies Global Healthcare Conference
SYK•
HomesToLife secures shareholder approval for SGX secondary listing preparations
HTLM•
60 Degrees Pharmaceuticals reports clinical improvement in all five completed babesiosis study patients
SXTP•